Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation.
A one-year-old boy with type I H mucopolysaccharidosis (Hurler's disease) was given a bone-marrow transplant (BMT) from his mother in an attempt to replace the deficient enzyme, alpha-L-iduronidase (iduronidase). These is definite evidence of engraftment, the enzyme activity of the recipient's leucocytes reaching heterozygote levels within 37 days of the BMT. Graft-versus-host disease (GVHD) developed but was partially controlled by steroids. From 3-4 months after graft until the present (13 months after the graft) iduronidase activity has been present in the serum and the urine and there has been evidence of considerable degradation of glycosaminoglycans excreted in the urine. The hepatosplenomegaly has disappeared, corneal clouding has cleared, and deterioration in the child's development seems to have been arrested.
D000609:Aminoacridines / Q000652:urine; D016026:Bone Marrow Transplantation; D006025:Glycosaminoglycans / Q000652:urine; D006801:Humans; D007068:Iduronidase / Q000097:blood / Q000652:urine; D007223:Infant; D007962:Leukocytes / Q000201:enzymology; D008297:Male; D008059:Mucopolysaccharidosis I / Q000201:enzymology / Q000628:therapy* / Q000652:urine; D009844:Oligosaccharides / Q000652:urine; D010290:Parents; D014574:Uronic Acids / Q000652:urine
D000609:Aminoacridines; D006025:Glycosaminoglycans; D009844:Oligosaccharides; D014574:Uronic Acids; D007068:Iduronidase